Centene
CNC
64.99
+0.38
+0.59%
Centene
US · CNC
#663 by market cap
Listed 1970
64.99
+0.38
+0.59%
Live - 5344 symbols - heartbeat 162s ago
· 2026-10-08 07:58
Pre-market
64.99
0.00%
After-hours
65.30
+0.48%
Overnight
64.90
-0.14%
- Market cap
- 32.10B
- P/E (TTM)i
- -6.27
- P/Bi
- 1.42
- EPSi
- -13.53
- Div yieldi
- 0.00%
- 52W posi
- 88%
Reader sentiment
Are you bullish or bearish on CNC?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.08, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +19.44% YoY
Margins
- Gross margin
- 7.12%
- Operating margin
- -0.16%
- Net margin
- -3.43%
Key ratios & quality
- Enterprise valuei
- 29.33B
- Altman Z-Scorei
- 3.08
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 60.12B | 74.64B | 111.12B | 125.98B | 144.55B | 154.00B | 163.07B | 194.78B |
| Gross profit | 8.42B | 8.84B | 15.22B | 14.20B | 16.66B | 17.32B | 16.83B | 13.87B |
| Selling & admin expenses | 6.75B | 6.53B | 11.34B | 9.60B | 11.59B | 12.56B | 12.40B | 12.90B |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.46B | 2.05B | 3.15B | 3.26B | 3.64B | 3.46B | 3.19B | -312.00M |
| Pretax profit | 1.37B | 1.78B | 2.77B | 1.81B | 1.96B | 3.60B | 4.26B | -6.73B |
| Tax | 474.00M | 473.00M | 979.00M | 477.00M | 760.00M | 899.00M | 963.00M | -51.00M |
| Net profit | 894.00M | 1.31B | 1.79B | 1.34B | 1.20B | 2.70B | 3.29B | -6.68B |
| Basic EPS | 2 | 3 | 3 | 2 | 2 | 5 | 6 | -14 |
| Diluted EPS | 2.26 | 3.14 | 3.12 | 2.28 | 2.07 | 4.95 | 6.31 | -13.53 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 46.62B | 48.74B | 49.69B | 49.73B | 49.94B | 53.58B |
| Gross profit | 5.20B | 2.95B | 3.25B | 2.47B | 5.56B | 4.60B |
| Selling & admin expenses | 3.35B | 3.04B | 3.15B | 3.37B | 3.40B | 3.10B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.53B | -403.00M | -211.00M | -1.23B | 1.86B | 1.20B |
| Pretax profit | 1.75B | -257.00M | -6.67B | -1.54B | 2.10B | 1.49B |
| Tax | 432.00M | 2.00M | -42.00M | -443.00M | 560.00M | 399.00M |
| Net profit | 1.31B | -259.00M | -6.63B | -1.10B | 1.54B | 1.09B |
| Basic EPS | 3 | -1 | -14 | -2 | 3 | 2 |
| Diluted EPS | 2.63 | -0.51 | -13.50 | -2.24 | 3.11 | 2.19 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 12.00B | 20.32B | 23.39B | 28.50B | 30.13B | 40.76B | 38.00B | 40.37B |
| Cash & ST investments | 6.06B | 12.99B | 12.38B | 14.66B | 14.40B | 19.65B | 16.69B | 20.32B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 30.90B | 40.99B | 68.72B | 78.38B | 76.87B | 84.64B | 82.45B | 76.75B |
| Total current liabilities | 11.97B | 12.93B | 21.59B | 25.77B | 28.46B | 36.72B | 34.26B | 36.70B |
| Short-term debt | 38.00M | 249.00M | 97.00M | 471.00M | 262.00M | 287.00M | 268.00M | 196.00M |
| Long-term debt | 6.65B | 13.64B | 16.68B | 18.57B | 17.94B | 17.71B | 18.42B | 17.35B |
| Total liabilities | 19,878,000,000.00 | 28,302,000,000.00 | 42,757,000,000.00 | 51,353,000,000.00 | 52,633,000,000.00 | 58,685,000,000.00 | 55,935,000,000.00 | 56,691,000,000.00 |
| Total equity | 11.02B | 12.69B | 25.96B | 27.02B | 24.24B | 25.96B | 26.51B | 20.06B |
| Retained earnings | 3.66B | 4.98B | 6.79B | 8.14B | 9.34B | 12.04B | 15.35B | 8.67B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 41.29B | 40.39B | 44.06B | 40.37B | 44.99B | 46.69B |
| Cash & ST investments | 17.29B | 17.28B | 19.24B | 20.32B | 23.74B | 27.06B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 87.04B | 86.40B | 82.09B | 76.75B | 81.18B | 83.01B |
| Total current liabilities | 37.14B | 36.79B | 40.63B | 36.70B | 40.05B | 40.76B |
| Short-term debt | 12.00M | 25.00M | 38.00M | 196.00M | 63.00M | 75.00M |
| Long-term debt | 18.31B | 17.55B | 17.55B | 17.35B | 16.31B | 16.03B |
| Total liabilities | 59,025,000,000.00 | 58,892,000,000.00 | 61,032,000,000.00 | 56,691,000,000.00 | 59,648,000,000.00 | 60,355,000,000.00 |
| Total equity | 28.02B | 27.50B | 21.06B | 20.06B | 21.53B | 22.66B |
| Retained earnings | 16.66B | 16.41B | 9.78B | 8.67B | 10.22B | 11.31B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.23B | 1.48B | 5.50B | 4.21B | 6.26B | 8.05B | 154.00M | 5.09B |
| Depreciation & amortization | 495.00M | 643.00M | 1.26B | 1.34B | 1.43B | 1.29B | 1.24B | 1.28B |
| Free cash flow | 559.00M | 753.00M | 4.63B | 3.30B | 5.26B | 7.25B | -490.00M | 4.32B |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 2.71B | -75.00M | -626.00M | -262.00M | -3.03B | -1.59B | -3.08B | -438.00M |
| Ending cash balance | 5.35B | 12.13B | 10.96B | 13.21B | 12.33B | 17.45B | 14.16B | 17.96B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 1.51B | 1.79B | 1.36B | 437.00M | 4.37B | 3.59B |
| Depreciation & amortization | 314.00M | 315.00M | 317.00M | 329.00M | 300.00M | 300.00M |
| Free cash flow | 1.38B | 1.58B | 1.15B | 224.00M | 4.17B | 3.42B |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -31.00M | -424.00M | 11.00M | 6.00M | -19.00M | 4.00M |
| Ending cash balance | 14.89B | 14.60B | 17.19B | 17.96B | 21.35B | 24.25B |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 10.13 | 11.26 | 9.44 | 5.12 | 4.73 | 10.83 | 12.65 | -28.79 |
| ROA %i | 3.41 | 3.67 | 3.30 | 1.83 | 1.55 | 3.35 | 3.96 | -8.38 |
| ROIC %i | 7.71 | 7.40 | 6.48 | 4.10 | 3.54 | 7.20 | 8.50 | -14.30 |
| 5-year avg ROE %i | 14.70 | 13.31 | 11.56 | 9.79 | 8.14 | 8.28 | 8.55 | 0.91 |
| EBIT margin %i | 2.85 | 2.94 | 3.15 | 1.97 | 1.82 | 2.81 | 3.04 | -3.11 |
| FCF / sales %i | 0.93 | 1.01 | 4.17 | 2.62 | 3.64 | 4.71 | -- | 2.22 |
| Current ratioi | 1.00 | 1.57 | 1.08 | 1.11 | 1.06 | 1.11 | 1.11 | 1.10 |
| Quick ratioi | 0.94 | 1.49 | 1.02 | 1.04 | 0.97 | 0.96 | 1.06 | 1.05 |
| Debt / assetsi | 21.64 | 35.39 | 24.42 | 28.91 | 27.75 | 22.30 | 23.57 | 23.66 |
| LT debt / equityi | 60.90 | 113.62 | 64.73 | 82.81 | 87.59 | 71.94 | 72.55 | 90.04 |
| Interest coveragei | 4.99 | 5.33 | 4.81 | 3.73 | 3.95 | 5.96 | 7.06 | -8.92 |
| Revenue CAGR (3Y) %i | 38.23 | 22.50 | 31.94 | 27.97 | 24.65 | 11.49 | 8.98 | 10.45 |
| Net income CAGR (3Y) %i | 36.36 | 32.96 | 29.73 | 14.39 | -3.10 | 14.33 | 34.88 | -- |
| FCF CAGR (3Y) %i | 3.24 | -21.30 | 63.15 | 80.64 | 91.12 | 16.11 | -- | -6.33 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 12.59 | 7.50 | -21.93 | -28.79 | -26.12 | -20.41 |
| ROA %i | 4.07 | 2.42 | -6.43 | -8.38 | -7.66 | -6.02 |
| ROIC %i | 8.73 | 5.70 | -11.39 | -14.30 | -14.38 | -11.25 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 3.09 | 1.93 | -2.24 | -3.11 | -2.88 | -1.96 |
| FCF / sales %i | 0.88 | 0.61 | 1.81 | 2.22 | 3.59 | 4.41 |
| Current ratioi | 1.11 | 1.10 | 1.08 | 1.10 | 1.12 | 1.15 |
| Quick ratioi | 1.07 | 1.06 | 1.04 | 1.05 | 1.08 | 1.11 |
| Debt / assetsi | 21.05 | 20.34 | 21.42 | 23.66 | 20.17 | 19.40 |
| LT debt / equityi | 65.58 | 64.04 | 83.76 | 90.04 | 76.11 | 71.05 |
| Interest coveragei | 7.53 | 5.01 | -6.09 | -8.92 | -8.49 | -6.07 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Medicaid is the largest reported line at 59.67% of revenue, across 4 reported segments.
- Medicare follows at 20.64%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Medicaid59.67%
Medicare20.64%
Commercial17.46%
Other/Eliminations2.23%
Quote time 2026-10-08 07:58:34 · For reference only, not investment advice and not tailored to your situation.